Clinical Trial · NCT06386653

Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1

Overview

The study should evaluate the biological distribution of \[123I\]I-DARPIN-Ec1 in patients with lung and ovarian cancer The primary objective are: 1. To assess the distribution of \[123I\]I-DARPIN-Ec1 in normal tissues and tumors at different time intervals. 2. To evaluate dosimetry of \[123I\]I-DARPIN-Ec1. 3. To study the safety and tolerability of the drug \[123I\]I-DARPIN-Ec1 after a single injection in a diagnostic dosage. The secondary objective are: 1\. To compare the obtained \[123I\]I-DARPIN-Ec1 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in lung and ovarian cancer patients.

Sponsor

Tomsk National Research Medical Center of the Russian Academy of Sciences

Phase

Phase 1

Contacts

Vladimir I Chernov, MD, Prof (STUDY_DIRECTOR)

ClinicalTrials.gov

NCT06386653

Drug / Compound

DARPIN-Ec1

Isotope(s):

Target(s):

EpCAM

Ligand Class: Small Proteins and Antibody Fragments

Eligibility

Inclusion

Clinical and radiological diagnosis of lung and ovarian cancer with histological verification.

Exclusion

Clinical and radiological diagnosis of lung and ovarian cancer with histological verification.